Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sarepta Therapeutics Fell 16.5% in September

By Maxx Chatsko - Oct 6, 2019 at 10:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock continued a slide that began in August, but shares have started heading higher again in October on the heels of promising clinical data.

What happened

Shares of Sarepta Therapeutics (SRPT 0.04%) slid over 16% last month, according to data from S&P Global Market Intelligence. The stock's September tumble was an extension of what began a month earlier, when two important pipeline assets made news for the wrong reasons. Last month was relatively quiet by comparison, but investors are still a little nervous over recent events.

The pessimism has weighed heavily on the biopharma stock. Shares of Sarepta Therapeutics are now down 35% in the past year and 42% since the beginning of July. Despite the recent mishaps, the company did report promising data for an early-stage drug candidate in the first few days of October.

An angry fist pounding the table while a declining stock chart displays on a tablet below.

Image source: Getty Images.

So what

The misery began in early August, when a patient in a phase 2 study evaluating the potential for micro-dystrophin to treat Duchenne muscular dystrophy (DMD) developed rhabdomyolysis. That triggered a submission to the U.S. Food and Drug Administration's (FDA) adverse event reporting system. Two weeks later, Sarepta Therapeutics received a complete response letter from the FDA related to its application seeking accelerated approval for golodirsen in DMD.

Investors had all of September to let the bad news sink in, but Sarepta Therapeutics reported promising data for an important drug candidate, a gene therapy called SRP-9003, in early October.

Three patients with Limb-girdle muscular dystrophy type 2E (LGMD2E) were given SRP-9003 and observed for nine months. Researchers witnessed consistent functional improvements, an important primary outcome; high levels of expression for the protein encoded by the gene therapy, suggesting it works at some level; and significantly reduced levels of creatine kinase, a key biomarker in muscular dystrophies. 

Sarepta Therapeutics still needs to study a higher dose of SRP-9003 before confirming the dose that will be used in a midstage clinical trial, but the positive trial paves the way for the company's four other drug candidates taking aim at different forms of Limb-girdle muscular dystrophies.

Now what

Sarepta Therapeutics has earned a $6.3 billion market valuation by staking out a leadership position in developing treatments for muscular disorders. Those difficult-to-treat conditions aren't exactly the easiest path to glory in the pharmaceutical industry, but the company has bagged more successes than failures. Investors just hope that continues so the business can grow into its premium valuation.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$109.04 (0.04%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.